Epidemiologi, faktor risiko, definisi dan manifestasi klinis COVID-19

Dr. Paul Harijanto, SpPD-KPTI

Pelatihan Penanganan Covid-19, Aula RSUP Kandouw, Rabu 29, 30 April 2020,

Perjalanan kejadian 2019-nCoV




Figure 1. Timeline of the key 2019-nCoV events.

Viruses 2020, 12, 135; doi:10.3390/v12020135

11 Feb2020 www.mdpi.com/jourରହା/ଜନ୍ମା/ଜନସାନ୍ତି

COVID-19

• WHO announced the current outbreak of coronavirus which was first reported from Wuhan, China, on December 31, 2019

 The virus has been named "SARS-CoV-2" and the disease it causes has been named "coronavirus disease 2019" (COVID-19)

THE THREE STRAINS OF CORONAVIRUS



Closest to coronavirus found in bats and pangolins Considered the 'root of the outbreak' Two sub-clusters - one linked to Wuhan and one common in America and Australia

TYPE B

Variation of coronavirus most common in Wuhan Derived from type 'A' via two mutations Mutates slowly in China but rapidly outside China TYPE C

Type C is the 'daughter' of type B One mutation different to parent variation Spread to Europe via Singapore



Novel Coronavirus (2019-nCoV) SITUATION REPORT - 1 21 JANUARY 2020

I. SURVEILLANCE

Data as reported by: 20 January 2 Reported incidence of confirmed 2019-nCoV cases

Table 1. Countries, territories or areas with reported confirmed cases of 2019-nCoV, 20 January


2020

Event highlights from 31 December

SUMMARY

WHO Regional Office	Country, territory, area	Total number of confirmed cases
WPRO	China – Hubei Province	258
	China – Guangdong	14
	China – Beijing Municipality	5
	China – Shanghai Municipality	1
	Japan	1
	Republic of Korea	1
SEARO	Thailand	2
Total confirmed		282
cases		

Details of cases reported on 20 January 2020:



Italy: 6.70 % (195,351 cases)

Spain: 7.67 % (223,759 cases)

France: 5.54 % (161,488 cases)

Germany: 5.37 % (156,513 cases)

United Kingdom: 5.09 % (148,377 cases)

Turkey: 3.69 % (107,773 cases)

Iran: 3.06 % (89,328 cases)

China: 2.84 % (82,827 cases)

Russia: 2.55 % (74,588 cases)

Brazil: 2.03 % (59,196 cases)

Canada: 1.55 % (45,354 cases)

Belgium: 1.55 % (45,325 cases)

Netherlands: 1.27 % (37,190 cases)

United State	s: 32.94 %	(960,651	cases)
--------------	------------	----------	--------


COVID-19 CORONAVIRUS PANDEMIC

Last updated: April 26, 2020, 06:39 GMT

USA 960,896 +245 54,265 +9 118,162 788,469 115,110 Spain 223,759 C 22,902 95,708 105,149 7,705 Italy 195,351 C 26,384 C 63,120 105,847 2,102 France 161,488 C 22,614 C 44,594 94,280 4,725 Germany 156,513 C 20,319 C N/A 127,714 1,559 Turkey 107,773 C 2,706 C 25,852 79,485 1,782 Iran 89,328 C 5,650 C 68,193 15,485 3,096								
Spain 223,759 22,902 95,708 105,149 7,705 Italy 195,351 26,384 63,120 105,847 2,102 France 161,488 22,614 44,594 94,280 4,725 Germany 156,513 5,877 109,800 40,836 2,570 UK 148,377 20,319 N/A 127,714 1,559 Turkey 107,773 2,706 68,193 15,485 3,096	World	2,923,009	+3,605	203,307	+143	837,156	1,882,546	57,870
Italy 195,351 26,384 63,120 105,847 2,102 France 161,488 22,614 44,594 94,280 4,725 Germany 156,513 5,877 109,800 40,836 2,570 UK 148,377 20 20,319 N/A 127,714 1,559 Turkey 107,773 22,706 68,193 15,485 3,096	USA	960,896	+245	54,265	+9	118,162	788,469	15,110
France 161,488 22,614 44,594 94,280 4,725 Germany 156,513 5,877 109,800 40,836 2,570 UK 148,377 20,319 N/A 127,714 1,559 Turkey 107,773 2,706 25,582 79,485 1,782 Iran 89,328 5,650 0 68,193 15,485 3,096	Spain	223,759		22,902		95,708	105,149	7,705
Germany 156,513 5,877 109,800 40,836 2,570 UK 148,377 20,319 N/A 127,714 1,559 Turkey 107,773 2,706 25,582 79,485 1,782 Iran 89,328 5,650 68,193 15,485 3,096	<u>Italy</u>	195,351		26,384		63,120	105,847	2,102
UK 148,377 20,319 N/A 127,714 1,559 Turkey 107,773 2,706 25,582 79,485 1,782 Iran 89,328 5,650 68,193 15,485 3,096	France	161,488		22,614		44,594	94,280	4,725
Turkey 107,773 2,706 25,582 79,485 1,782 Iran 89,328 5,650 68,193 15,485 3,096	<u>Germany</u>	156,513		5,877		109,800	40,836	2,570
Iran 89,328 5,650 68,193 15,485 3,096	<u>UK</u>	148,377		20,319		N/A	127,714	1,559
	<u>Turkey</u>	107,773		2,706		25,582	79,485	1,782
China 82,827 +11 4,632 77,394 801 51	Iran	89,328		5,650		68,193	15,485	3,096
	China	82,827	+11	4,632		77,394	801	51

Total number of cases

Per country over time



RISK FACTORS :

Strong

- residence in/travel to location reporting community transmission during the 14 days prior to symptom onset
- close contact with a confirmed case
- older age and/or underlying health conditions
- obesity
- smoking
- malignancy
- surgery





Figure 1. WHO reported exposure mechanisms of COVID-19 SARS-CoV-2 droplets (dark blue bowr). Light blue colour: airborne mechanism that is known from SARS-CoV-1 and other flu, currently there is no reported evidence specifically for SARS-CoV-2 (figure: courtesy Francesco Franchimon).

Comparison with other viruses


For comparison, the incubation period for the common flu (sea: Incubation period for other coronaviruses: SARS 2-7 days; MEI


Virus	Incubation Period Coronavirus Incubation Period: Last updated: February 23, 2:00 GMT
Novel Coronavirus (2019-nCoV)	2 - 14 days Possible outliers: 0 - 27 days
SARS	<u>2-7 days,</u> as long as 10 days
MERS	<u>5 days</u> (range: 2-14)
Swine Flu	<u>1-4 days,</u> as long as 7 days
Seasonal Flu	2 days (1-4 range)

Age Distribution and Case Fatality Rate COVID-19 China through 11-Feb-2020 (N = 44,672 confirmed cases)



adapte





The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020

The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team


(Chinese Center for Disease Control and Prevention, CCDC Weekly / Vol. 2 / No. 8)


COVID-19 Fatality Rate by COMORBIDITY:

PRE-EXISTING CONDITION	DEATH RATE
Cardiovascular disease	10.5%
Diabetes	7.3%
Chronic respiratory disease	6.3%
Hypertension	6.0%
Cancer	5.6%
no pre-existing conditions	0.9%

COVID-19 Fatality Rate by AGE:

AGE		DEATH RATE
80+ years old		14.8%
70-79 years old		8.0%
60-69 years old		3.6%
50-59 years old		1.3%
40-49 years old		0.4%
30-39 years old		0.2%
20-29 years old		0.2%
10-19 years old		0.2%
	0-9 years old	no fatalities





References:

1. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Lauer SA et al. Ann Intern Med. 2020 Mar 10.

2. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand. Neil M Ferguson et al. Imperial College COVID-19 Response Team. 16 March 2020.

3. Viral dynamics in mild and severe cases of Covid-19. Yang Liu et al. The Lancet, March 19, 2020.

Novel Coronavirus Outbreak (2019-nCoV)

Symptoms* of Novel Coronavirus

Patients with 2019-nCoV have reportedly had mild to severe respiratory illness with symptoms of:

FeverCough

Shortness of breath

* Symptoms may appear 2-14 days after exposure. If you have been in China within the past 2 weeks and develop symptoms, call your doctor.

www.cdc.gov/nCoV



CS 314705-B

Features of Confirmed Cases in China

Data source: 43,113 confirmed cases from China Information System for Disease Control and Prevention

Asymptomatic cases 2% (n=724)

-laboratory testing positive but without symptoms

Mild cases 81% (n=34869)


-including non-pneumonia cases and mild pneumonia cases

Severe cases 14% (n=6210)

- Difficulty in breathing, respiratory rate \geq 30 times/min, Oxygen saturation \leq 93%, PaO2/FiO2 \leq 300, the area of diffuse patchy infiltration greater than 50% of the lungs in 24 to 48h.


Critical cases 3% (n=1310)

- Respiratory failure, septic shock, MODS/MOF
- Elderly, patients with underlying diseases, obesity or a decreased lymphocyte count face poor prognosis
 Illness Severity COVID-19 - China through 11-Feb-2020



The symptoms of coronavirus disease [COVID-19] Our World

The most common signs and symptoms of 55,924 laboratory confirmed cased of COVID-19. Reported from China in the period up to February 22, 2020



Data source: World Health Organization (2020), Report of the WHO-China Juint Mission on Coronavirus Disease 2019 (COVID-19), Symptoms in fewer than 1% are not shown. OurWorldinData.org - Research and data to make progress against the world's largest problems. Licensed under CC-BY by the authors.

GEJALA KLINIS

Symptoms near the time of presentation in various cohorts


	Guan et al. NEJM (largest cohort)	Shi et al Lancet	Yang et al. Lancet (critically ill pts)	Chen et al.	Huang et al.	Xu et al. BMJ
Constitutional						
Fever	473/1081 (43%)	18/21 (86%)	46/52 (88%)	82/99 (83%)	40/41 (98%)	48/62 (77%)
Myalgia	164/1081 (15%)		6/52 (12%)	11/99 (11%)		
Headache	150/1081 (14%)	2/21 (10%)	3/52 (6%)	8/99 (8%)	2/38 (8%)	21/62 (34%)
Upper respirator	Y					
Rhinorrhea	53/1081 (5%)	5/21 (24%)	3/52 (6%)	4/99 (4%)		
Sore throat	153/1081 (14%)			5/99 (5%)		
Lower respirator	У					
Dyspnea	205/1081 (19%)	9/21 (43%)	33/52 (64%)	31/99 (31%)	22/40 (55%)	2/62 (3%)
Chest tightness		5/21 (24%)				
Cough	745/1081 (68%)	15/21 (71%)	40/52 (77%)	81/99 (82%)	31/41 (76%)	50/62 (81%)
Sputum	370/1081 (34%)	3/21 (14%)			11/39 (28%)	35/62 (56%)
Hemoptysis	10/1081 (1%)				2/39 (5%)	2/62 (3%)
Gastrointestinal						
Nausea/Vomiting	55/1081 (5%)	2/21 (10%)	2/52 (6%)	1/99 (1%)		
Diarrhea	42/1081 (4%)	1/21 (5%)		2/99 (2%)	1/38 (3%)	3/62 (8%)

The most common symptoms are: [20] [21] [39] [136] [137] [138]

- Fever
- Cough
- Dyspnoea
- Myalgia
- Fatigue
- Anosmia/dysgeusia.

Less common symptoms include:

- Anorexia
- Sputum production
- Conjunctivitis
- Gastrointestinal symptoms
- Sore throat
- Confusion
- Dizziness
- Headache
- Rhinorrhoea or nasal congestion
- Chest pain
- Haemoptysis
- Cutaneous manifestations.



RESPIRATORY MANIFESTATIONS

- UPPER RESPIRATORY INFECTIONS (Cold, Pharyngitis)
- LOWER RESPIRATORY INFECTIONS PNEUMONIA :
 - CAP : Infection of the pulmonary parenchyma acquired from exposure in the community


Classically divided into "typical" and "atypical" syndromes:

- I. <u>"Typical" CAP:</u>
 - presents with "typical" severe, acute infection
 - infectious agent (usually S. pneumo or H. flu) is culturable/ identifiable
 - responsive to cell-wall active antibiotics

II. <u>"Atypical" CAP:</u>


- presentation is usually sub-acute
- causative pathogens are difficult to culture/identify by standard methods
- not responsive to penicillins
- Viral pneumonia


Figure 3 Cardiovascular involvement in COVID-19 - key manifestations and hypothetical mechanisms



SARS-CoV-2 anchors on trans-membrane ACE2 to enter the host cells including type-2 pneumocytes, macrophages, endothelial cells, pericytes and cardiac myocytes leading to inflammation and multi-organ failure. Infection of endothelial cells or pericytes is of particular importance because this could lead to severe microvascular and macrovascular dysfunction. In addition, immune over-reactivity can potentially destabilize atherosclerotic plaques and explain the development of acute coronary syndromes. Infection of the respiratory tract, particularly type-2 pneumocytes, by SARS-CoV-2 is manifested by the progression of systemic inflammation and immune cell over-activation leading to "cytokine storm", resulting in increased levels of cytokines such as IL-6, IL-7, IL-22 and CXCL10. Subsequently, it is possible that activated T cell and macrophages may infiltrate infected myocardium resulting in the development of fullminant myocarditis and severe cardiac damage. This process may be further intensified by a cytokine storm. Similarly, the viral invasion may cause cardiac myocyte damage directly leading to myocardial dysfunction and contribute to the development of arrhythmias. From Guzik et al., COVID-19 and the cardiovascular system - implications for risk assessment, diagnosis and treatment options. Cardiovasc Res., 2020, doi: 10.1093/cvr/cvaa106.¹⁰

MANIFESTASI KARDIO VASKULER







MANIFESTASI SISTIM KULIT

no

Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy

Yangli Liu[#], Haihong Chen[#], Kejing Tang, Yubiao Guo* 13 patients :3 pts discharged uncomplicated pregnancy

10 pts SC (5 emergency due to : with multidicipline approach)

- 3 Fetal distress
- 1 Premature rupture of membrane
- 1 stillbirth
- 6 pts (46%), preterm labour 32-36 weeks due to
 - MOF, ARDS, ARF, ALF, septic shock
- 12 pts discharged
- 1 pts severe pneumonia

Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study

Nan Yu*, Wei Li *, Qingling Kang, Zhi Xiong, Shaoshu ai Wang, Xingguang Lin, Yanyan Liu, Juan Xiao, Haiyi Liu, Dongrui Deng, Suhua Chen, Wanjiang Zeng, Ling Feng, Jianli Wu

7 pts , 37-41 weeks

- All SC
- 2 pts chronic ilness hypothyroid & POS
- 3 uterine scraring
- Multidisicipline approach
- Good outcome for mothers and child





Review Article

Central nervous system manifestations of COVID-19: A systematic review



Ali A. Asadi-Pooya^{a,b,*}, Leila Simani^c

^a Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

^b Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, USA

^cSkull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti Univsersity of Medical Sciences, Tehran, Iran

Neurological manifestations :

febrile seizures, convulsions, change in mental status, and encephalitis, nasal infection,, causing inflammation and demyelination [




FIGURE 1 Neurological manifestations in COVID-19. Fever with headaches (A) may occur early in COVID-19 patients. Specific manifestations related to neurological deficits like loss of smell, taste, ataxia and convulsions have been

MANIFESTASI SISTIM SARAF

JAMA Neurology | Original Investigation

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China

Ling Mao; Huijuan Jin; Mengdie Wang; Yu Hu; Shengcai Chen; Quanwei He; Jiang Chang; Candong Hong; Yifan Zhou; David Wang; Xiaoping Miao; Yanan Li, MD, PhD; Bo Hu, MD, PhD

214 pts, 36.4% had neurological manifestations :

- CNS : Headache, dizziness, convulsion, 24.8%
- Peripheral Nervous S: 8.9%, taste & smell impairment
- Skeletal muscle injury: 10,7%

Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission

Yuan Tian 💿 | Long Rong 💿 🕴 Weidong Nian 🕴 Yan He

Incidence of 3% (1/41)-79% (159/201), gastrointestinal symptoms of COVID-19 included:

- anorexia 39.9% (55/138)-50.2% (101/201),
- diarrhoea 2% (2/99)-49.5% (146/295),
- vomiting 3.6% (5/138)-66.7% (4/6),
- nausea 1% (1/99)-29.4% (59/201),
- abdominal pain 2.2% (3/138)-6.0% (12/201) and
- gastrointestinal bleeding 4% (2/52)-13.7% (10/73).

MANIFESTASI GASTRO INTESTINAL & HATI

Gastrointestinal and liver manifestations in patients with COVID-19

I-Cheng Leeab, Teh-Ia Huoa.c.d., Yi-Hsiang Huangab.e.

*Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, *Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC; *Department of Medicine, Taipei, Taipei, Taiwan, ROC; *Department of Medicine, Taipei, Taiwan, ROC; *Department of Medicine, Taipei, Taipei, Taiwan, ROC; *Department of Medicine, Taipei, Taiwan, ROC; *Department of Medicine, Taipei, Taipei, Taiwan, ROC; *Department of Medicine, Taipei, Taipei, Taipei, Taipei, *Department of Medicine, Taipei, *Department, ROC; *Department of Medicine, Taipei, *Department, *Departmen

- 2 11% Liver co morbid
- 16 -53% Abnormal ALT and AST
- The more severe covid-19, the more higher liver abnormality

Hematology's Indispensable Role in COVID-19 Diagnosis & Prognosis

Blood test for COVID-19


- A. WBC: normal or increased (24-3 patients)^{3,4}
- B. Lymphocyte count and percenta decreased(63% of 41 patients)³
- C. CRP: increased (86% of 73 patie
- D. Eosinophil count: decreased⁵

A new prognosis indicator - NLR

NLR is **N**eutrophil to **L**ymphocyte count **R**atio, it's calculated from CBC result, **easy-to-use** parameter.

Study⁶ in Beijing showed that cut-off value of NLR is 3.13, sensitivity is 0.875 and specificity is 0.717.

Patients should be transferred to ICU with age >50 and NLR>3.13. If NLR<3.13 and age<50, the patients could isolate at home or community hospita




ELSEVIER

Contents lists available at ScienceDirect

Asian Journal of Psychiatry

journal homepage: www.elsevier.com/locate/ajp



Psychiatric

Manifestation in

Covid-19

COVID-19 and mental health: A review of the existing literature

Ravi Philip Rajkumar

Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, 605 006, India

- Occur in patient, public & health workers
- Anxiety 44.7%
- Stress 73.4%
- Depression 50.7^c Article
- Emotion
- Insomnia 36.1%

Patients with mental health disorders in the COVID-19 epidemic

Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China

Cuiyan Wang ¹⁽¹⁾, Riyu Pan ¹, Xiaoyang Wan ¹, Yilin Tan ¹, Linkang Xu ¹, Cyrus S. Ho ^{2,3}⁽¹⁾ and Roger C. Ho ^{1,3,4,*}⁽¹⁾

Endocrine Manifestation in Covid-19

COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology

M. Puig-Domingo¹ · M. Marazuela² · A. Giustina^{3,4}

Keywords Covid-19 · Diabetes mellitus · Obesity · Malnourishment · Hypoadrenalism

- DIABETES increased mortality & morbidity
- OBESITY
- UNDERNOURISHMENT
- HYPOADRENALISM

Ophthalmic Manifestations Of Coronavirus (COVID-19)

Katherine Hu; Jay Patel; Bhupendra C. Patel.

Author Information

Last Update: April 13, 2020.

Ocular manifestations of COVID-19 are overall rare in the published literature. Only 9 (0.8%) out of 1,099 patients from 552 hospitals across 30 provinces in China were reported to have "conjunctival congestion."[7]

A recent case series reported ocular symptoms in 12 (31.6%) of 38 hospitalized patients with COVID-19 in Hubei province, China.[8] These 12 of 39 patients had conjunctival hyperemia (3 patients), chemosis (7 patients), epiphora (7 patients), or increased secretions (7 patients). Of note is that one patient who had epiphora presented with epiphora as the first symptom of COVID-19. Of those with ocular manifestations, 2 (16.7%) patients had positive results of SARS-CoV-2 on reverse-transcriptase polymerase chain reaction (RT-PCT) by a conjunctival swab as well as by nasopharyngeal swabs. Only one patient in this study presented with conjunctivities as the first symptom.[8] The authors noted that patients with ocular symptoms had higher white blood cell and neutrophil counts, C-reactive protein, and higher levels of procalcitonin and lactate dehydrogenase compared to patients without ocular abnormalities.

MANIFESTASI PADA MATA " Conjunctival congestion " Conjunctival hyperaemia Chemosis Epiphora Increased secretions PERSPECTIVES IN RHEUMATOLOGY

MANIFESTASI SISTIM MUSCULO-SKELETAL



Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets

Durga Prasanna Misra¹ . Vikas Agarwal¹ . Armen Yuri Gasparyan² . Olena Zimba³

Table 1 Manifestations associated with coronavirus disease 19 (COVID-19) mimicking rheumatic syndromes

- 1. Arthralgias and Myalgias
- Cytopenias: leucopenia (predominantly lymphopenia); thrombocytopenia
- 3. Acute interstitial pneumonia-like presentation
- 4. Myocarditis
- 5. Secondary hemophagocytic lymphohistiocytosis and cytokine storm
- 6. Possible greater risk of venous thromboembolism

Case Definition And Surveillance

Global surveillance for COVID-19 caused by human infection with COVID-19 virus Interim guidance 20 March 2020 World Health Organization

Background

This document summeries corner WHO goidness on global unvaillance for COVID-19 in humans, caused by infaction with COVID-19 trims. This guidance should be read in conjunction with WHO's guidance on <u>propurabans</u>, madiana, and response derivities, which temply incommands to then case finding and buding as well as context tracing in all remainiston scannics. Aggregate separating should be considered a temportry stop-gap measures only what individual case sporting is not possible. WHO will contain the typical this produces a new information about COVID-19 becomes straibilds.

Updated information and other guidance on COVID-19 can be found on the WHO COVID-19 website

What is new:

- · Updated case definition for a probable case
- Definition of transmission pattern
- Revision of the definition of a contact
- Update on global surveillance with aggregated data reporting

Purpose of this document

This document provides guidance to Member States on implementation of global surveillance for COVID-19.

Objectives of the surveillance

The objectives of the global surveillance are to:

- 1. Monitor trends in COVID-19 disease at national and global levels.
- 2. Rapidly detect new cases in countries where the virus is not circulating, and monitor cases in countries where the virus has started to circulate.
- Provide epidemiological information to conduct risk assessments at the national, regional and global level.
 Provide epidemiological information to guide preparedness and response measures.

Case definitions for surveillance

Case and contact definitions are based on the current available information and are regularly revised as new information accumulate. Countries may need to adapt case definition depending on their local epidemiological situation and other factors . All countries are accuraged to public definitions used entime and in regular transition resport, and to document periodic updates to definitions which may affect the interpretation of surveillance data.

Suspect case

A A paisan with acute requiratory illuses (force and at least one sign/symptom of requiratory disease, e.g., cough, shortness of breath), AND a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom cause;

OR

B. A patient with any acute respiratory illness AND having been in contact with a confirmed or probable COVID-19 case (see definition of contact) in the last 14 days prior to symptom onset;

0

C. A paintar with seven scale registrary illness (force and at least one sign/symptom of respiratory disease, e.g., cough, shortness of treats; AND requiring hospitalization) AND in the absence of an alternative diagnosis that fully explains the clinical presentation.

- ILI and Pneumonia surveillance have to be strengthened AND ensure all ILI and/or pneumonia cases being asked for travel history, residences and possible close contact-→ meet case definition
- If suspected case found, immediately contact local authority for further follow up on case investigation and contact tracing as containment measure.

Case Definitions:

Case Definition Surveillance				
Close Contact:	 Face-to-face contact with a probable or confirmed case within 1 meter and for more than 15 minutes; Direct physical contact with a probable or confirmed case; Direct care for a patient with probable or confirmed COVID-19 disease without using proper personal protective equipment; Other situations as indicated by local risk assessments. 			
Suspect:	 Patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath), AND a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset Patient with any acute respiratory illness AND having been in contact with a confirmed or probable COVID-19 case in the last 14 days prior to symptom onset Patient with severe acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath; AND requiring hospitalization) AND in the absence of an alternative diagnosis that fully explains the clinical presentation 			


Case Definitions:

Case Definition After Testing Performed			
Confirmed:	 A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms 		
Probable:	 A suspect case for whom testing for the COVID-19 virus is inconclusive. A suspect case for whom testing could not be performed for any reason 		

OTG	ODP	PDP - Proba	ble - Confirmed
		KeMenKes RI Mare	t 2020. PPPI COVID-19 Rev -03
Tanpa Gejala	Gejala Awal	Pneumonia	Inflamasi berat
hat —			005000
Ge	ha	i. h	
Virus berreplikasi di nasofaring Ikubasi virus 3-14 (median 5) hari	Virus berreplikasi dan berikatan dg reseptor ACE2 di organ	Peningkatan respons imun pejamu	Inflamasi sistemik tidak terkendal Bedal sitokin.
Pasien tiada gejala	Demam, batuk kering, pilek, nyeri tenggorok, sakit kepala, sakit otot, mual , diare.	Demam persisten, sesak, hipoksemia, Temuan radiologi kelainan paru	ARDS, Sepsis, Mickarditis, Gagal multi organ
PCR dan Ag mungkin positif Ab (IgM, IgG) negatif	PCR dan Ag positif titer tertinogi. Ab igM mungkin mulai positif hart 3-6. IgG biasa masih negatif	PCR dan Ag masih positif Ab (IgM memuncak, IgG mulai positif (hari ke8/10)	PCR dan Ag masih positif. Ab igM masih positif. igG meningkat



Current diagnosis and treatment of COVID-19



CASE REPORT



COVID-19 Pneumonia in Asymptomatic Trauma Patients; Report of 8 Cases

Majid Samsami¹, Javad Zebarjadi Bagherpour¹*, Behzad Nematihonar¹, Hamed Tahmasbi¹

1. Department of General Surgery, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Received: April 2020; Accepted: April 2020; Published online: 6 April 2020

Hu et all :

- 24 cases asymptomatic :
 - 20.8% developed stmptom fever, cough
 - 50 % typical GGO
 - 20.8% strip shadowing in the lung
 - 29.2% normal CT scan & symptoms
 - None have symptoms fever, cough, breathless, headache
 - 62.5% had history of contact cases Covid-19
 - Physical exam no abnormality of pneumonia
 - CT scan strongly pneumonia
 - 25 % developed symptom
 - 50% CRP increased

Baseline characteristics	Confirmed cases,	Deaths,	Case fatality	Observed time,	Mortality,
Denvisor	N (%)	N (%6)	rate, %	PD	per 10 PD
Province					
Hubei	33,367 (74.7)	979 (95.7)	2.9	496,523	0.020
Other	11,305 (25.3)	44 (4.3)	0.4	165,086	0.003
Wuhan-related exposure*					
Yes	31,974 (85.8)	853 (92.8)	2.7	486,612	0.018
No	5,295 (14.2)	66 (7.2)	1.2	71,201	0.009
Missing	7,403	104	2.8	103,796	0.010
Comorbid condition [†]					
Hypertension	2,683 (12.8)	161 (39.7)	6.0	42,603	0.038
Diabetes	1,102 (5.3)	80 (19.7)	7.3	17,940	0.045
Cardiovascular disease	873 (4.2)	92 (22.7)	10.5	13,533	0.068
Chronic respiratory disease	511 (2.4)	32 (7.9)	6.3	8,083	0.040
Cancer (any)	107 (0.5)	6 (1.5)	5.6	1,690	0.036
None	15,536 (74.0)	133 (32.8)	0.9	242,948	0.005
Missing	23,690 (53.0)	617 (60.3)	2.6	331,843	0.019
Case severity [§]					
Mild	36,160 (80.9)	-	-	-	-
Severe	6,168 (13.8)	-	-	-	-
Critical	2,087 (4.7)	1,023 (100)	49.0	31,456	0.325
Missing	257 (0.6)	-	-	-	-

COVID-19

- On January 30, 2020, the International Health Regulations Emergency Committee of the World Health Organization declared the outbreak a "public health emergency of international concern external icon" (PHEIC).
- On January 31, 2020, Health and Human Services Secretary Alex M. Azar II declared a public health emergency (PHE) for the United States to aid the nation's healthcare community in responding to COVID-19.

Clinical manifestations

- The incubation period: the incubation period is 1-14 days, mostly 3-7 days.
- Clinical Features:
 - Fever, dry cough, fatigue as the main performance.
 - A small number of patients have symptoms such as stuffy nose, runny nose, sore throat, myalgia and diarrhea.
 - In severe cases, dyspnea and/or hypoxemia usually occur one week after the onset of the disease, and dyspnea and/or hypoxemia may rapidly progress to acute respiratory distress syndrome, septic shock, metabolic acidosis that is difficult to correct, bleeding and coagulation dysfunction, and multiple organ failure.
- The patients with severe or critical illness may have moderate or low fever, or even no significant fever.
- The mild patients showed only low fever, mild fatigue, and no pneumonia.
- Most patients have a good prognosis, a few patients are in critical condition. The elderly and those with chronic underlying diseases have poor prognosis.

Findings from the Huang et al study published on The Lancet and based on 41 hospitalized patients ^[3]

COMMON SYMPTOMS AT ONSET OF ILLNESS (Huang et al study) ^[3]	
Fever	98%
Cough	76%
Myalgia (muscle pain) or Fatigue	44%
LESS COMMON SYMPTOMS:	
Sputum production (coughing up material)	28%
Headache	8%
Haemoptysis (coughing up blood)	5%
Diarrhea	3%

Full list of symptoms from the Wang study:

	No. (%)	No. (%)		
	Total (N = 138)	ICU (n = 36)	Non-ICU (n = 102)	P Value ²
igns and symptoms				
Fever	136 (98.6)	36 (100)	100 (98.0)	>.99
Fatigue	96 (69.6)	29 (80.6)	67 (65.7)	.10
Dry cough	82 (59.4)	21 (58.3)	61 (59.8)	.88
Anorexia	55 (39.9)	24 (66.7)	31 (30.4)	<.001
Myalgia	48 (34.8)	12 (33.3)	36 (35.3)	.83
Dyspnea	43 (31.2)	23 (63.9)	20 (19.6)	<.001
Expectoration	37 (26.8)	8 (22.2)	29 (28.4)	.35
Pharyngalgia	24 (17.4)	12 (33.3)	12 (11.8)	.003
Diarrhea	14 (10.1)	6 (16.7)	8 (7.8)	.20
Nausea	14 (10.1)	4 (11.1)	10 (9.8)	>.99
Dizziness	13 (9.4)	8 (22.2)	5 (4.9)	.007
Headache	9 (6.5)	3 (8.3)	6 (5.9)	.70
Vomiting	5 (3.6)	3 (8.3)	2 (2.0)	.13
Abdominal pain	3 (2.2)	3 (8.3)	0 (0)	.02
Inset of symptom to, median (IQR), d				
Hospital admission	7.0 (4.0-8.0)	8.0 (4.5-10.0)	6.0 (3.0-7.0)	.009
Dyspnea	5.0 (1.0-10.0)	6.5 (3.0-10.8)	2.5 (0.0-7.3)	.02

Table 1. Baseline Characteristics of Patients Infected With 2019-nCoV



Suspected case

Based on the epidemiologic characteristics observed so far in China, everyone is assumed to be susceptible, although there may be risk factors increasing susceptibility to infection.

 A patient with acute respiratory tract infection (sudden onset of at least one of the following: cough, fever, shortness of breath) AND with no other aetiology that fully explains the clinical presentation AND with a history of travel or residence in a country/area reporting local or community transmission during the 14 days prior to symptom onset;

OR

 A patient with any acute respiratory illness AND having been in close contact with a confirmed or probable COVID-19 case in the last 14 days prior to onset of symptoms;

OR

 A patient with severe acute respiratory infection (fever and at least one sign/symptom of respiratory disease (e.g., cough, fever, shortness breath)) AND requiring hospitalisation (SARI) AND with no other aetiology that fully explains the clinical presentation.

Probable case

A suspected case for whom testing for virus causing COVID-19 is inconclusive (according to the test results reported by the laboratory) or for whom testing was positive on a pan-corona virus assay.

Confirmed case

A person with laboratory confirmation of virus causing COVID-19 infection, irrespective of clinical signs and symptoms

Close contact of a probable or confirmed case is defined as

- A person living in the same household as a COVID-19 case;
- A person having had direct physical contact with a COVID-19 case (e.g. shaking hands);
- A person having unprotected direct contact with infectious secretions of a COV ID-19 case (e.g. being coughed on, touching used paper tissues with a bare hand);
- A person having had face-to-face contact with a COVID-19 case within 2 metres and > 15 minutes;
- A person who was in a closed environment (e.g. classroom, meeting room, hospital waiting room, etc.) with a COVID-19 case for 15 minutes or more and at a distance of less than 2 metres;
- A healthcare worker (HCW) or other person providing direct care for a COVID-19 case, or laboratory workers handling specimens from a COVID-19 case without recommended personal protective equipment (PPE) or with a possible breach of PPE;
- A contact in an aircraft sitting within two seats (in any direction) of the COVID-19 case, travel companions or persons providing care, and crew members serving in the section of the aircraft where the index case was seated (if severity of symptoms or movement of the case indicate more extensive exposure, passen gers seated in the entire section or all passengers on the aircraft may be consid ered close contacts). ^[56]

CLINICAL COURSE & DISCHRGE / MORTALITY

Lancet: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study <u>https://buff.ly/2W63buS</u>

